Bioextrax
Bioextrax is a Swedish biotechnology company that develops process technologies for producing bioplastics from renewable raw materials and for extracting protein and microfibers from feathers. The company was founded in 2014 on research from Lund University and operates as a technology developer and licensor rather than a large-scale manufacturer.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueBiobased process technology for producing biodegradable PHA polymers from renewable inputs.
Processes that recover protein from feathers for use in feed and other applications.
Technology for producing microfibers from feathers for industrial and material uses.
Licenses and related commercialization agreements for Bioextrax technologies.
Customers
Bioextrax sells primarily to industrial partners that want to commercialize its process technologies through licensing agreements. Its customer base includes chemical companies, materials producers, and other manufacturers seeking lower-energy, lower-chemical routes to biobased materials. The feather-based technologies also point to potential customers in feed and ingredient markets that can use recovered protein and fibers.
They license PHA process technology to produce biodegradable plastics at commercial scale.
They evaluate and adopt Bioextrax processes for pilot plants and first commercial facilities.
They use feather-derived protein as an input for feed or related applications.
They use feather microfibers or biobased outputs in niche industrial applications.
Strategy
Bioextrax’s strategy is to commercialize its platform through multiple licensing agreements and partner-led scale-up rather than building a capital-intensive manufacturing footprint. It aims to expand the number of customers and collaborators using its PHA and feather-processing technologies, while proving that the processes can be deployed at industrial scale.
Licensing fits the company’s technology model and avoids heavy manufacturing investment.
PHA is the core bioplastic application and the main route to industrial relevance.
More partners increase validation, revenue opportunities, and technology reach.
Geography
Bioextrax is headquartered in Sweden and its technology base is tied to Lund University research. The business is global in commercial ambition because its licensing model targets industrial partners outside Sweden, but the reports provided do not disclose a country revenue split.
Risks
Bioextrax depends on converting technical development into signed licenses and partner adoption, so commercialization risk is central to the business. As a development-stage licensor, it also faces funding risk if recurring license revenue does not grow fast enough to support operations, alongside typical scale-up and execution risks in new bioprocess technologies.
- Commercialization and adoption riskImpact: HighLikelihood: High
Revenue comes mainly from licensing, so delays in partner conversion directly affect income.
Exposure: License agreements and partner pipeline
- Funding and liquidity riskImpact: HighLikelihood: High
The company may need external capital if license income is insufficient to fund operations.
Exposure: Operating cash burn and financing needs
- Scale-up and technical execution riskImpact: High
Industrial partners must validate and implement the processes at commercial scale.
Exposure: PHA process deployment and first plant build-out
- Competitive technology riskImpact: Medium
Alternative bioplastic and protein-recovery technologies may offer lower cost or easier deployment.
Exposure: PHA and feather-processing markets
Accounting
Judgemental itemsNet sales are mainly license income, so contract timing and performance obligations affect reported revenue.
Impact: Quarterly revenue can shift with new agreements and milestones
Grants, FX gains, and sick pay reimbursements are included outside core sales.
Impact: Can distort comparability with license revenue
Management evaluates whether future license income and financing are sufficient to continue operations.
Impact: Affects disclosure and investor assessment of liquidity risk
Commercialization-stage companies often have uneven inflows and development spending.
Impact: Makes interim cash generation difficult to extrapolate
Similar listed companies
Publicly listed companies with a comparable business focus.
BioInvent International
BINV · Health Care
BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy.
BioNexus Gene Lab Corp
BGLC · Services-Medical Laboratories
BioNexus Gene Lab Corp is a U.S.-listed holding company with operating subsidiaries in Malaysia that combines genomic screening services with industrial chemical trading.
Biodesix, Inc
BDSX · Services-Medical Laboratories
Biodesix is a U.S.-based diagnostic solutions company focused on lung disease testing and diagnostic development services.
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Kraig Biocraft Laboratories, Inc.
KBLB · Plastic Material, Synth Resin/Rubber, Cellulos (No Glass)
Repligen Corporation
RGEN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026